

Impact of Process and Quality Control on the Physicochemical Properties of Tobramycin Ophthalmic Ointments


Shilpa Patere¹, Bryan Newman², Stephanie Choi², Yan Wang², Michael Jay³, Xiuling Lu¹

¹Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA

²Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, U.S. Food and Drug Administration, Silver Spring, MD, USA

³Division of Pharmacoengineering & Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

INTRODUCTION




- Tobramycin (TOB), a water soluble aminoglycoside antibiotic, was selected as the model drug and Tobrex® (0.3% w/w) ophthalmic ointment, manufactured by Alcon as the reference product
- In house prepared qualitative (Q1) and quantitative (Q2) equivalent ointments (with low percent of API, 0.3% w/w) manufactured using different processes can have different physicochemical properties that may lead to variation in performance
- Understanding the impact of process and quality control parameters on product performance is critical for developing generic ophthalmic semisolids

OBJECTIVE

- To prepare Q1/Q2 oleaginous ointments using different preparation methods, sources of excipients and TOB API
- To investigate the feasibility of *in vitro* techniques in identifying critical process and quality attributes to discriminate Q1/Q2 ointments

METHODS



Sample ID	Method of preparation	PET USP source
DoE-1	U2	C
DoE-2	U1	B
DoE-3	L	B
DoE-4	U1	A
DoE-5	U2	B
DoE-6	L	A
DoE-7	U2	A
DoE-8	L	A
DoE-9	U1	C
DoE-10	L	C
DoE-11	U1	B
DoE-12	U2	C

Twelve DoE ointments (Q1/Q2) were prepared using TOB Z, three different sources of PET USP (A, B and C) and preparation methods (L, U1 and U2)

Method	Level	Speed (rpm)	Mixing time (Min.)	Resting time (Min.)
U1	3	1130	9	5
	2	970	1	5
	1	810	1	5
U2	9	2100	9	5
	2	970	1	5
	1	810	1	5

L: Levigation, U1 and U2: Unguator high speed mixing method 1 and 2

Statistical analysis: Analysis of variance (ANOVA) with Tukey's was used for comparing all the parameters. P<0.05 was considered statistically significant.

RESULTS

Representative microscopic images (Scale bar: 40µm, 50x magnification)




Table 1: Particle size analysis of three TOB API (n=3)

Source of TOB	D ₁₀ (µm)	D ₅₀ (µm)	D ₉₀ (µm)	D ₉₉ (µm)
X	2.23±0.2	5.80±0.5	24.6±2.3	53.67± 1.7
Y	1.46±0.18	4.6±0.5	9.33±0.6	13.6±0.9
Z	1.26±0.17	3.94±0.2	7.53±0.6	11±0.3

- Results suggested no significant influence of preparation technique on particle size reduction of TOB API

Content Uniformity

- Content uniformity of ointments with TOB Y and TOB Z were in the acceptable range of 90-110% with deviation from mean within ±10%
- Larger TOB particles from source X reduced the homogeneity of ointments with high SD due to low percent content of TOB (0.3% w/w)




Fig. 1: MTDSC of TOB X, Y, Z and Tobrex®

- MTDSC of TOB Z demonstrated major endothermic peak at 220°C corresponding to the monohydrate form of TOB and comparable to the endothermic peak of Tobrex® (Fig. 1)

GC-MS




Fig. 2: GC-MS chromatograms A) PET B) Ointments with their PET and Tobrex®

- All three PET produced individual chromatographic fingerprints depicting differences in their composition (Fig. 2A)
- Chromatograms of ointments were comparable to their PET but with a shift in the hump intensity on higher side
- Ointments with PET A, B and Tobrex® showed broad range of linear alkanes (C21-C33) with high peak intensities (Fig. 2B)
- PET C and ointments with PET C showed narrow distribution of linear alkanes (C22-C27) with low peak intensities suggesting presence of large amounts of highly branched and ring paraffin's (Fig. 2B)

TGA




Fig. 3: TGA analysis A) TOB Z B-D) Ointments with their pure PET base E) Tobrex®

- Different derivative loss peaks in TGA signify presence of components with different degradation profiles
- TOB from all three sources showed comparable derivative weight loss peaks (Fig. 3A)
- DoE 4 (PET A) and DoE 2 (PET B) demonstrated minor and major loss peaks comparable to the pure PET base used in their preparation (Fig. 3B and C)
- Loss peak intensity of DoE 9 (PET C) was shifted on lower side compared to pure PET C which could be due to the breaking of highly branched chains and/or some change in the microstructure of PET C during high speed mixing process (Fig. 3D). Derivative loss peaks of Tobrex® showed a major peak at 337°C and a minor peak at 247°C (Fig. 3E).

Rheological studies




Fig. 4: Yield stress by strain sweep (n=3) **Fig. 5:** Representative G' and G'' by strain sweep (40°C) **Fig. 6:** Viscosity by steady state flow (n=3) **Fig. 7:** Viscosity by temperature sweep at 0.1% strain (n=3)




Fig. 8: G' of 12 DoE ointments by strain sweep method (40°C, n=3)

- Statistical difference between the yield stress by strain sweep method was comparable at all the studied temperatures (Fig. 4)
- Rheological parameters [storage modulus (G') and loss modulus (G'')] were found to be different for the three PET sources at 40°C (Fig. 5)
- Ointments demonstrated shear thinning behavior in the steady state flow method using cone geometry (Fig. 6)




Fig. 9: Impact of method of preparation and source of PET on yield stress and G' (40°C)

- Statistical difference between viscosity by temperature sweep method was comparable from 35°C to 40°C (Fig. 7)
- Variations were observed in the rheological parameters of all the DoE ointments (Fig. 8)
- PET source showed more significant influence on rheological parameters compared to the method of preparation (Fig. 9)

CONCLUSION

- Particle size distribution of API is crucial to obtain good content uniformity in ophthalmic ointments with low percent of API
- Differences in the hydrocarbon composition and rheological parameters of the PET source influence the properties and quality attributes of oleaginous ophthalmic ointments
- Source of PET plays a more critical role in determining the rheological properties of ointments compared to the method of preparation

FUNDING

Funding for this project was made possible, in part, by the Food and Drug Administration through grant 1U01FD005174-01. The views expressed in this poster do not reflect the official policies of the U.S. Food and Drug Administration or the U.S. Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.